Compare PFSI & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFSI | ABCL |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | 2018 | 2020 |
| Metric | PFSI | ABCL |
|---|---|---|
| Price | $75.30 | $11.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $128.11 | $8.40 |
| AVG Volume (30 Days) | 667.3K | ★ 8.2M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 59.25 | 10.91 |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $984,629,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.96 | $21.85 |
| P/E Ratio | $39.34 | ★ N/A |
| Revenue Growth | 3.05 | ★ 160.56 |
| 52 Week Low | $71.68 | $2.75 |
| 52 Week High | $160.36 | $11.65 |
| Indicator | PFSI | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 39.69 | 80.64 |
| Support Level | $71.68 | $3.38 |
| Resistance Level | $87.46 | N/A |
| Average True Range (ATR) | 2.31 | 0.82 |
| MACD | -0.06 | 0.54 |
| Stochastic Oscillator | 45.78 | 92.37 |
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform mainly focused on the production and servicing of U.S. residential mortgage loans. The firm is also engaged in managing investments related to the U.S. mortgage market and provides products and services that leverage technologies to support customers. The company operates through two reportable operating segments: production and servicing. The production segment performs loan origination, acquisition, and sale activities, while the servicing segment performs servicing and subservicing of loans, early buyout transactions, and servicing of loans sourced and managed for PMT. The majority of revenue comes from the production segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.